People · Operator
Named in public records as an officer, director or promoter · active 2025–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Electra Therapeutics, Inc. | — | Biotechnology | Series D+ | $134.2M | $962.3M | 2025 |
Nancy Stagliano, Ph.D. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Nancy Stagliano, Ph.D. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Matthew Fust | 1 | 4 |
| Beth Seidenberg, M.D. | 1 | 3 |
| Carl Gordon, Ph.D. | 1 | 2 |
| Thomas Geninatti, Ph.D. | 1 | 1 |
| Quehuong (Kathy) Dong, Pharm.D. | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.